Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
General Hospital Corporation
Boston, MA US
| General Hospital Corporation Patent applications | ||
| Patent application number | Title | Published |
|---|---|---|
| 20100047787 | PROSTATE CANCER SURVIVAL AND RECURRENCE - The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to prostate cancer. In particular, the disclosure is based on the identities of genes that are correlated with patient survival and prostate cancer recurrence. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats and used to predict the survival of subjects afflicted with prostate cancer and to predict prostate cancer recurrence. The profiles may also be used in the study and/or diagnosis of prostate cancer cells and tissue as well as for the study and/or determination of prognosis of a patient. When used for diagnosis or prognosis, the profiles may be used to determine the treatment of prostate cancer based upon probable life expectancy and cancer recurrence and/or metastasis. | 02-25-2010 |
| 20090275502 | METHODS AND COMPOSITIONS FOR ENHANCING DEVELOPMENTAL POTENTIAL OF OOCYTES AND PREIMPLANTATION EMBRYOS - The invention relates to compositions and methods for enhancing the developmental potential of oocytes or preimplantation embryos by modulating mitochondrial-associated proteins and/or genomic integrity modifier proteins in the oocytes or preimplantation embryos. In one aspect of the invention, the levels of one or more mitochondrial-associated proteins and/or genomic integrity modifier proteins are increased, in particular by introducing the mitochondrial-associated proteins and/or genomic integrity modifier proteins into the oocytes or preimplantation embryos. Oocytes may be fertilized to obtain a zygote with increased levels of one or more mitochondrial-associated proteins and/or genomic integrity modifier proteins. The methods and compositions may be used to improve in vitro fertilization and embryo transfer methods, and nuclear transfer techniques. | 11-05-2009 |